Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation.
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation.
复制标题
DOI：
10.3389/fonc.2022.1054497
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Chi, Kim N. N.
中科院分区：
文献类型：
--
作者：
Kwan, Edmond M. M.;Wyatt, Alexander W. W.;Chi, Kim N. N.
血浆循环肿瘤DNA（ctDNA）代表主要从经历细胞凋亡的癌细胞释放到血流中的肿瘤衍生DNA的短片段。在转移性去势抵抗性前列腺癌（mCRPC）中，表征ctDNA中的基因组改变可识别具有预测和预后生物标志物效用的突变、拷贝数改变和结构重排。这些与临床结果的关联导致ctDNA越来越多地被纳入常规临床护理。在这篇综述中，我们总结了ctDNA分析在转移性前列腺癌中的当前和新兴应用，包括结果预测，治疗选择和治疗抗性的表征。我们还讨论了解释ctDNA结果的潜在陷阱，即由低肿瘤含量和最佳检测设计引起的假阴性，包括校正不确定潜力和种系变异的克隆造血。理解这些限制对ctDNA结果解释的影响对于克服临床实施的障碍是必要的。然而，随着检测可用性和技术的不断改进，认识到ctDNA分析的机会和缺点将保持与实施转移性前列腺癌的精确肿瘤学倡议的相关性。
Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine clinical care. In this review, we summarize current and emerging applications for ctDNA analysis in metastatic prostate cancer, including outcome prediction, treatment selection, and characterization of treatment resistance. We also discuss potential pitfalls with interpreting ctDNA findings, namely false negatives arising from low tumor content and optimal assay design, including correction for clonal hematopoiesis of indeterminate potential and germline variants. Understanding the influence of these limitations on interpretation of ctDNA results is necessary to overcome barriers to clinical implementation. Nevertheless, as assay availability and technology continue to improve, recognizing both opportunities and shortcomings of ctDNA analysis will retain relevance with informing the implementation of precision-oncology initiatives for metastatic prostate cancer.
登录
查看更多内容
影响因子：
4.6
作者：
Abida W;Armenia J;Gopalan A;Brennan R;Walsh M;Barron D;Danila D;Rathkopf D;Morris M;Slovin S;McLaughlin B;Curtis K;Hyman DM;Durack JC;Solomon SB;Arcila ME;Zehir A;Syed A;Gao J;Chakravarty D;Vargas HA;Robson ME;Joseph V;Offit K;Donoghue MTA;Abeshouse AA;Kundra R;Heins ZJ;Penson AV;Harris C;Taylor BS;Ladanyi M;Mandelker D;Zhang L;Reuter VE;Kantoff PW;Solit DB;Berger MF;Sawyers CL;Schultz N;Scher HI
通讯作者：
Scher HI
影响因子：
4.8
作者：
Bryce, A. H.;Alumkal, J. J.;Beer, T. M.
通讯作者：
Beer, T. M.
具有转移性cast割前列腺癌的男性的鲁卡巴里（Rucaparib）具有BRCA1或BRCA2基因改变。
DOI：
10.1200/jco.20.01035
发表时间：
2020-11-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Abida W;Patnaik A;Campbell D;Shapiro J;Bryce AH;McDermott R;Sautois B;Vogelzang NJ;Bambury RM;Voog E;Zhang J;Piulats JM;Ryan CJ;Merseburger AS;Daugaard G;Heidenreich A;Fizazi K;Higano CS;Krieger LE;Sternberg CN;Watkins SP;Despain D;Simmons AD;Loehr A;Dowson M;Golsorkhi T;Chowdhury S;TRITON2 investigators
通讯作者：
TRITON2 investigators
DOI：
10.1056/evidoa2200043
发表时间：
2022-09-01
期刊：
NEJM evidence
影响因子：
--
作者：
Clarke, Noel W;Armstrong, Andrew J;Saad, Fred
通讯作者：
Saad, Fred
影响因子：
23.4
作者：
Casanova-Salas I;Athie A;Boutros PC;Del Re M;Miyamoto DT;Pienta KJ;Posadas EM;Sowalsky AG;Stenzl A;Wyatt AW;Mateo J
通讯作者：
Mateo J